Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Globus Medical GMED has seen impressive momentum in the past year, with its shares soaring 62.1%. It has significantly outperformed the industry’s 7.3% rise and the S&P 500 composite’s 24.8% gain.

which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Globus Medical: mixed. While the ...

Globus Medical will acquire Nevro for $250 million in cash, enhancing its musculoskeletal technology portfolio andglobal marketreach. Globus Medical and Nevro Corp. have agreed on an all-cash ...

Globus Medical (GMED) appears an attractive pick ... to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual ...

Consensus $2.5B. “2024 was an exceptional year of execution and achievement for Globus Medical (GMED). With the NuVasive merger, we believe we created the strongest sales force and best product ...

On Thursday, BofA Securities analyst Craig Bijou upgraded shares of Globus Medical (NYSE:GMED), a medical device company, from Underperform to Neutral and increased the price target to $97 from $80.